- Home
- VCNX vs IMCC Comparison
VCNX vs IMCC Comparison
Compare VCNX & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- IMCC
- Stock Information
- Founded
- VCNX 2001
- IMCC 1980
- Country
- VCNX United States
- IMCC Israel
- Employees
- VCNX N/A
- IMCC N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- VCNX Health Care
- IMCC Health Care
- Exchange
- VCNX Nasdaq
- IMCC Nasdaq
- Market Cap
- VCNX 4.5M
- IMCC 5.0M
- IPO Year
- VCNX N/A
- IMCC N/A
- Fundamental
- Price
- VCNX $3.22
- IMCC $2.81
- Analyst Decision
- VCNX
- IMCC
- Analyst Count
- VCNX 0
- IMCC 0
- Target Price
- VCNX N/A
- IMCC N/A
- AVG Volume (30 Days)
- VCNX 167.3K
- IMCC 27.2K
- Earning Date
- VCNX 11-29-2024
- IMCC 11-14-2024
- Dividend Yield
- VCNX N/A
- IMCC N/A
- EPS Growth
- VCNX N/A
- IMCC N/A
- EPS
- VCNX N/A
- IMCC N/A
- Revenue
- VCNX $388,000.00
- IMCC $38,042,859.00
- Revenue This Year
- VCNX N/A
- IMCC $22.59
- Revenue Next Year
- VCNX N/A
- IMCC $20.53
- P/E Ratio
- VCNX N/A
- IMCC N/A
- Revenue Growth
- VCNX N/A
- IMCC N/A
- 52 Week Low
- VCNX $1.39
- IMCC $1.13
- 52 Week High
- VCNX $13.02
- IMCC $8.10
- Technical
- Relative Strength Index (RSI)
- VCNX 48.87
- IMCC 71.25
- Support Level
- VCNX $2.87
- IMCC $1.84
- Resistance Level
- VCNX $3.43
- IMCC $3.34
- Average True Range (ATR)
- VCNX 0.53
- IMCC 0.26
- MACD
- VCNX 0.05
- IMCC 0.10
- Stochastic Oscillator
- VCNX 23.22
- IMCC 64.78
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.